スタッフ紹介

学歴

2002年3月

北海道旭川東高等学校卒業

2008年3月

北海道大学医学部医学科卒業

2017年3月

北海道大学大学院医学研究科医学専攻　博士課程修了

職務経歴

2008年4月

札幌社会保険総合病院　初期研修医

2010年4月

JA北海道厚生連 網走厚生病院　内科・消化器内科　医員

2011年4月

市立函館病院　消化器内科　医員

2013年4月

北海道大学病院　消化器内科　医員

2014年4月

国立がん研究センター東病院　消化管内科　短期レジデント

2016年4月

北海道大学病院　腫瘍センター　医員

2017年4月

釧路労災病院　内科・腫瘍内科　副部長

2018年4月

釧路労災病院　内科・腫瘍内科　部長

2020年4月

現職

所属学会・資格

• 日本内科学会　認定医
• 日本消化器病学会　専門医
• 日本臨床腫瘍学会　専門医
• 日本癌治療学会
• 日本消化器内視鏡学会
• 米国臨床腫瘍学会（ASCO）
• 欧州腫瘍学会（ESMO）
• 日本がんサポーティブケア学会

趣味

料理

論文
（英文のみ）

1. Kawamoto Y, Sawada K, Harada K, Motoo I, Ando T, Sogabe S, Kobayashi Y, Dazai M, Nakamura M, Hatanaka K, Ishiguro A, Sato A, Nakano S, Shindo Y, Hosokawa A, Ito K, Yoshikawa A, Ueda A, Iuchi K, Yokota I, Yuki S, Komatsu Y.
   A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).
   Gastric Cancer. 2026 Jul;29(4):808-815. doi: 10.1007/s10120-026-01751-w. Epub 2026 May 4.
   PMID: 42081056 Free PMC article. Clinical Trial.
2. Sakakida T, Masuishi T, Onoe T, Komine K, Yonemori K, Fujisawa T, Harada K, Hamauchi S, Tokumo K, Esaki T, Hiroshima Y, Watanabe S, Asayama M, Hosoda W, Taniguchi H, Hayashi H, Muro K.
   Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design).
   Future Oncol. 2026 May;22(11):1273-1279. doi: 10.1080/14796694.2026.2658642. Epub 2026 Apr 15.
   PMID: 41985019 Clinical Trial.
3. Sano Y, Ozaka M, Aoki S, Nomura S, Mitome N, Fukuda H, Mizui T, Kamei K, Murakawa M, Eguchi H, Kawai M, Shirakawa H, Yagi S, Mizuno N, Takahashi A, Takahashi H, Ikenaga N, Okano N, Marubashi S, Nagakawa Y, Kobayashi S, Okazaki T, Harada K, Akita H, Otsuru T, Kagawa S, Hirono S, Seo S, Arima S, Gotohda N, Fujii T, Hatano E, Unno M, Ueno M; Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group.
   Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).
   Jpn J Clin Oncol. 2026 Jul 6;56(7):904-909. doi: 10.1093/jjco/hyag055.
   PMID: 41968990 Clinical Trial.
4. Harada K, Kajiura S, Sawada K, Hatanaka K, Sato A, Ito K, Tamura H, Doi A, Ando T, Nakamura M, Nakatsumi H, Muranaka T, Sogabe S, Ishii T, Nakano S, Dazai M, Sasaki Y, Kawamoto Y, Yuki S, Sakata Y, Komatsu Y.
   Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201).
   Support Care Cancer. 2026 Feb 19;34(3):221. doi: 10.1007/s00520-026-10445-z.
5. Kanno R, Saito Y, Takekuma Y, Harada K, Komatsu Y, Sugawara M.
   Successful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report.
   J Pharm Health Care Sci. 2025 Dec 22;11(1):110. doi: 10.1186/s40780-025-00514-6.
   PMID: 41430346 Free PMC article.
6. Harada K, Ishida K, Kaneko S, Yokoyama T, Sawaguchi S, Nakamura T, Kawamoto Y, Yuki S, Nishida M, Sakamoto N, Komatsu Y.
   Ultrasound-detected gastric changes related to zolbetuximab-induced emesis: a case series.
   Front Oncol. 2025 Nov 28;15:1686245. doi: 10.3389/fonc.2025.1686245. eCollection 2025.
   PMID: 41395595 Free PMC article.
7. Matsuda S, Tsushima T, Kawakubo H, Hironaka S, Tsubosa Y, Sakanaka K, Oguma J, Kadowaki S, Tsunoda S, Hara H, Koyanagi K, Yamaguchi T, Harada K, Takahashi M, Minashi K, Baba E, Sasaki K, Machida R, Takeuchi H.
   Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314.
   Esophagus. 2026 Jan;23(1):111-119. doi: 10.1007/s10388-025-01163-2. Epub 2025 Oct 29.
   PMID: 41160311 Clinical Trial.
8. Kaneko S, Harada K, Ohara M, Sawaguchi S, Yokoyama T, Ishida K, Kawamoto Y, Yuki S, Komatsu Y, Sakamoto N.
   Urinary Titin as a Non-Invasive Biomarker for Sarcopenia Sex Differences in Unresectable Digestive Malignancies: A Retrospective Cohort Study.
   Int J Mol Sci. 2025 Jul 15;26(14):6781. doi: 10.3390/ijms26146781.
   PMID: 40725028 Free PMC article.
9. Nakamura T, Hatanaka KC, Kawamoto Y, Kaneko S, Ishida K, Harada K, Yuki S, Komatsu Y, Hatanaka Y, Sakamoto N.
   Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma.
   J Cancer Res Clin Oncol. 2025 May 10;151(5):159. doi: 10.1007/s00432-025-06216-8.
   PMID: 40346357 Free PMC article.
10. Sugiura R, Kawamoto Y, Kuwatani M, Kawakubo K, Harada K, Ohara M, Yonemura H, Nozawa S, Sakamoto N.
    Subcutaneous adipose tissue radiodensity as a predictor of poor prognosis in advanced biliary tract cancer.
    J Hepatobiliary Pancreat Sci. 2025 Mar;32(3):194-202. doi: 10.1002/jhbp.12105. Epub 2025 Jan 8.
    PMID: 39779323 Free article.
11. Toji Y, Takeuchi S, Ebihara Y, Kurashima Y, Harada K, Hayashi M, Abe H, Wada H, Yorinaga S, Shichinohe T, Tomaru U, Komatsu Y, Hirano S.
    Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series.
    Surg Case Rep. 2024 Aug 28;10(1):200. doi: 10.1186/s40792-024-02001-w.
    PMID: 39192090 Free PMC article.
12. Nakatsumi H, Komatsu Y, Harada K, Kawamoto Y, Yuki S, Sawada K, Ishiguro A, Sogabe S, Ando T, Sasaki Y, Yoshikawa A, Nakamura M, Dazai M, Tateyama M, Muto O, Kotaka M, Sagawa T, Muranaka T, Hatanaka K, Takagi R, Sakata Y.
    A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801.
    Int J Cancer. 2024 Dec 15;155(12):2223-2231. doi: 10.1002/ijc.35116. Epub 2024 Aug 14.
    PMID: 39143041 Clinical Trial.
13. Ueda A, Yuki S, Ando T, Hosokawa A, Nakada N, Kito Y, Motoo I, Ito K, Sakumura M, Nakayama Y, Ueda Y, Kajiura S, Nakashima K, Harada K, Kawamoto Y, Komatsu Y, Yasuda I.
    CA125 Kinetics as a Potential Biomarker for Peritoneal Metastasis Progression following Taxane-Plus-Ramucirumab Administration in Patients with Advanced Gastric Cancer.
    Cancers (Basel). 2024 Feb 22;16(5):871. doi: 10.3390/cancers16050871.
    PMID: 38473233 Free PMC article.
14. Harada K, Yuki S, Kawamoto Y, Nakamura T, Kaneko S, Ishida K, Sakamoto N, Komatsu Y.
    Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases.
    Ther Adv Med Oncol. 2023 Nov 28;15:17588359231216090. doi: 10.1177/17588359231216090. eCollection 2023.
    PMID: 38033418 Free PMC article.
15. Harada K, Yamamura T, Muto O, Nakamura M, Sogabe S, Sawada K, Nakano S, Yagisawa M, Muranaka T, Dazai M, Tateyama M, Kobayashi Y, Kato S, Hatanaka K, Kawamoto Y, Yuki S, Sakata Y, Sakamoto N, Komatsu Y.
    Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101).
    J Clin Med. 2023 Feb 17;12(4):1596. doi: 10.3390/jcm12041596.
    PMID: 36836140 Free PMC article.
16. Nakatsumi H, Komatsu Y, Muranaka T, Yuki S, Kawamoto Y, Harada K, Dazai M, Tateyama M, Sasaki Y, Miyagishima T, Tsuji Y, Katagiri M, Nakamura M, Sogabe S, Hatanaka K, Meguro T, Kobayashi T, Ishiguro A, Muto O, Shindo Y, Kotaka M, Ando T, Takagi R, Sakamoto N, Sakata Y.
    Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
    Front Oncol. 2022 Nov 9;12:939425. doi: 10.3389/fonc.2022.939425. eCollection 2022.
    PMID: 36439491 Free PMC article.
17. Saito R, Kawamoto Y, Nishida M, Iwai T, Kikuchi Y, Yokota I, Takagi R, Yamamura T, Ito K, Harada K, Yuki S, Komatsu Y, Sakamoto N.
    Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome.
    Int J Clin Oncol. 2022 Nov;27(11):1780-1790. doi: 10.1007/s10147-022-02235-4. Epub 2022 Aug 30.
    PMID: 36042137 Free PMC article.
18. Kawamoto Y, Yuki S, Sawada K, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Meguro T, Harada K, Sekiguchi M, Okada K, Ito YM, Sakata Y, Sakamoto N, Komatsu Y.
    Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
    Oncologist. 2022 Aug 5;27(8):e642-e649. doi: 10.1093/oncolo/oyac086.
    PMID: 35579511 Free PMC article. Clinical Trial.
19. Ito K, Yuki S, Nakatsumi H, Kawamoto Y, Harada K, Nakano S, Saito R, Ando T, Sawada K, Yagisawa M, Ishiguro A, Dazai M, Iwanaga I, Hatanaka K, Sato A, Matsumoto R, Shindo Y, Tateyama M, Muranaka T, Katagiri M, Yokota I, Sakata Y, Sakamoto N, Komatsu Y.
    Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.
    Support Care Cancer. 2022 Jun;30(6):5351-5359. doi: 10.1007/s00520-022-06936-4. Epub 2022 Mar 15.
    PMID: 35292848 Free PMC article.
20. Harada K, Okamoto W, Mimaki S, Kawamoto Y, Bando H, Yamashita R, Yuki S, Yoshino T, Komatsu Y, Ohtsu A, Sakamoto N, Tsuchihara K.
    Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
    BMC Cancer. 2019 Mar 21;19(1):255. doi: 10.1186/s12885-019-5479-6.
    PMID: 30898102 Free PMC article.
21. Harada KOgasawara M, Shido A, Meno A, Oda S, Yoshida S, Yoshida S, Yoshikawa A, Ebata K, Abiko S, Kawagishi N, Sano I, Oda H, Miyagishima T.
    Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
    Thorac Cancer. 2020 Mar 17.
22. Abiko S, Yoshikawa A, Harada K, Kawagishi N, Sano I, Oda H, Miyagishima T.
    New ligation technique using a double loop clip without adhesive for ulceration following endoscopic submucosal dissection of the colon.
    Endoscopy. 2020 Jan;52(1):E20-E21.
23. Abiko S, Yoshikawa A, Harada K, Kawagishi N, Sano I, Oda H, Miyagishima T.Harada K
    Usefulness of a clutch cutter combined with an S-O clip in improving stability when opening the pocket in the pocket-creation method.
    Endoscopy, 2019 Oct 25.
24. Harada KOkamoto W, Mimaki S, Kawamoto Y, Bando H, Yamashita R, Yuki S, Yoshino T, Komatsu Y, Ohtsu A, Sakamoto N, Tsuchihara K.
    Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
    BMC Cancer. 2019 Mar 21;19(1):255.
25. Kawamoto Y, Komatsu Y, Yuki S, Sawada K, Muranaka T, Harada K, Nakatsumi H, Fukushima H, Ishiguro A, Dazai M, Hatanaka K, Nakamura M, Iwanaga I, Uebayashi M, Sogabe S, Kobayashi Y, Miyagishima T, Ono K, Sakamoto N, Sakata Y.
    Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
    BMC Cancer. 2017 Dec 8;17(1):837.
26. Muranaka T, Yuki S, Komatsu Y, Sawada K, Harada K, Kawamoto Y, Nakatsumi H, Sakamoto N.
    Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience.
    J Gastric Cancer. 2016 Sep;16(3):177-181.